(Q48610657)

13 February 2018

title

Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo (English)

1 reference

13 February 2018

author name string

J Y Ryu

1

1 reference

13 February 2018

I S Song

2

1 reference

13 February 2018

Y E Sunwoo

3

1 reference

13 February 2018

J H Shon

4

1 reference

13 February 2018

K H Liu

5

1 reference

13 February 2018

I J Cha

6

1 reference

13 February 2018

J G Shin

7

1 reference

13 February 2018

language of work or name

English

0 references

publication date

28 March 2007

1 reference

13 February 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

13 February 2018

volume

82

1 reference

13 February 2018

issue

5

1 reference

13 February 2018

page(s)

531-540

1 reference

13 February 2018

Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Clinical importance of the cytochromes P450

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Influence of nutrients and other dietary materials on cytochrome P-450 enzymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Assessment of cytochrome P450 activity by a five-drug cocktail approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Reduction of liver plasma flow by caffeine and theophylline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Cocktail strategy: complications and limitations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

CYP2C19 genotype and phenotype determined by omeprazole in a Korean population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Determination of omeprazole in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100187

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100187

1 reference

13 February 2018

1 reference

13 February 2018